Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials
- 1 November 2014
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 86 (2) , 133-136
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2013
- Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesotheliomaCancer Science, 2012
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet Oncology, 2011
- Projection of mesothelioma mortality in Britain using Bayesian methodsBritish Journal of Cancer, 2010
- Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2009
- Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II StudyJournal of Thoracic Oncology, 2008
- Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810)Lung Cancer, 2008
- High‐dose ifosfamide with mesna and granuloctye–colony‐stimulating factor (recombinant human G‐CSF) in patients with unresectable malignant mesotheliomaCancer, 2003
- Combined regimen of cisplatin, doxorubicin, and ?-2b interferon in the treatment of advanced malignant pleural mesotheliomaCancer, 2001
- Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BLung Cancer, 2001